Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cyclophosphamide 30

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    377 result(s) found for: Cyclophosphamide 30. Displaying page 13 of 19.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next» Last»»
    EudraCT Number: 2011-005856-32 Sponsor Protocol Number: RITULUP Start Date*: 2012-05-21
    Sponsor Name:Fundación Progreso y Salud
    Full Title: Comparison of the efficacy of two rituximab treatment regimens in patients with lupus nephropathy resistant to conventional treatment
    Medical condition: Long-term relapse after treatment of lupus nephritis (LN) resistant to conventional treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002011-24 Sponsor Protocol Number: 42205525 Start Date*: 2008-05-22
    Sponsor Name:European Group for Blood and Marrow Transplantation (EBMT)
    Full Title: Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study
    Medical condition: Myelodysplastic syndromes and secondary acute myeloid leukaemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004053-88 Sponsor Protocol Number: EuroNet-PHL-C2 Start Date*: 2015-07-01
    Sponsor Name:Justus-Liebig-University Giessen
    Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents
    Medical condition: Hodgkin lymphoma in children and adolescents
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended) NL (Completed) DK (Prematurely Ended) FR (Ongoing) PL (Prematurely Ended) FI (Completed) GB (GB - no longer in EU/EEA) SE (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000391-28 Sponsor Protocol Number: 951404713 Start Date*: 2017-09-20
    Sponsor Name:INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
    Full Title: A PHASE II, DOUBLE-BLIND, CONTROLLED, PARALLEL-ARM TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INFUSION OF ALLOGENIC MESENCHYMAL STEM CELLS IN LUPUS NEPHRITIS (LN)
    Medical condition: LUPUS NEPHRITIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002088-16 Sponsor Protocol Number: CD19-CAR01 Start Date*: 2017-12-22
    Sponsor Name:Bambino Gesù Children's Hospital
    Full Title: Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma
    Medical condition: Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10018849 Haematological disorders NEC HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001258-25 Sponsor Protocol Number: HM20/123197 Start Date*: 2020-05-14
    Sponsor Name:University of Leeds
    Full Title: Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell trans...
    Medical condition: Newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-000806-64 Sponsor Protocol Number: BLT004973 Start Date*: 2007-08-01
    Sponsor Name:Barts Health NHS Trust
    Full Title: A Phase II Trial of Sequential treatment with Cytoreductive therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/ Refractory Acute Myeloid Leukemia, High Ris...
    Medical condition: Relapsed/ Refractory Acute Myeloid Leukemia, High Risk Myelodysplasia,or other High Risk Myeloid Malignancies
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004936-36 Sponsor Protocol Number: CLL13 Start Date*: 2016-11-08
    Sponsor Name:University of Cologne
    Full Title: A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) ve...
    Medical condition: fit patients with previously untreated CLL without del(17p) or TP53 mutation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed) AT (Completed) FI (Completed) BE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000720-17 Sponsor Protocol Number: MOM-M281-006 Start Date*: 2020-01-14
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension
    Medical condition: Adults with Warm Autoimmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10002285 Anemia hemolytic autoimmune (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Temporarily Halted) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000072-42 Sponsor Protocol Number: RG_11-087 Start Date*: 2013-02-06
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DK (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Completed) AT (Completed) DE (Prematurely Ended) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003260-28 Sponsor Protocol Number: KT-US-473-0133 Start Date*: 2022-07-18
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
    Medical condition: Relapsed and/or Refractory Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004851 10085262 Follicular lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000121-32 Sponsor Protocol Number: 68284528MMY2001 Start Date*: 2019-09-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000371-34 Sponsor Protocol Number: NKV20001 Start Date*: 2005-01-25
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title: A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769...
    Medical condition: Chemotherapy-Induced Nausea and Vomiting (CINV) - Highly Emetogenic Chemotherapy (HEC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) AT (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003815-25 Sponsor Protocol Number: CP0101-CLL Start Date*: 2022-02-21
    Sponsor Name:CellPoint B.V.
    Full Title: A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (C...
    Medical condition: relapsed / refractory Chronic Lymphocytic Leukemia relapsed / refractory Small Lymphocytic Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003856-35 Sponsor Protocol Number: Uni-Koeln-3946 Start Date*: 2020-12-18
    Sponsor Name:University of Cologne
    Full Title: Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA)
    Medical condition: multiple myeloma (untreated)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003350-25 Sponsor Protocol Number: SPON1751-19 Start Date*: 2019-09-05
    Sponsor Name:Cardiff University
    Full Title: An open label, 3-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib in combination with either Chemotherapy or Blinatumomab with Imatinib plus Chemotherapy as front-line...
    Medical condition: Philadelphia chromosome positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukaemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021600-24 Sponsor Protocol Number: FEC Start Date*: 2010-10-16
    Sponsor Name:IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
    Full Title: FEC neo-adjuvant chemotherapy followed by weekly Taxol administration combined with Trastuzumab in II-III stage HER2 positive breast cancer patients.Fase II trial.
    Medical condition: II/III stage HER2+ eligible for neoadjuvant chemotherapy breast cancer women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007308 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001969-49 Sponsor Protocol Number: N15TON Start Date*: 2015-09-03
    Sponsor Name:NKI-AvL
    Full Title: Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple-negative breast cancer (TNBC) patients: TONIC-trial
    Medical condition: Triple negative breast cancer (TNBC) patients with metastatic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020826 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001244-95 Sponsor Protocol Number: MK-3475-C11 Start Date*: 2021-07-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
    Medical condition: Classical Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003629-45 Sponsor Protocol Number: IOV-LUN-202 Start Date*: 2021-05-05
    Sponsor Name:Iovance Biotherapeutics, Inc.
    Full Title: A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN -145) in Patients with Metastatic Non-Small-Cell Lung Cancer
    Medical condition: Metastatic Non-Small-Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 9  10  11  12  13  14  15  16  17  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 08:59:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA